Key Points
- CeriBell Director Joseph Michael Taylor sold 13,095 shares at an average price of $23.40, generating $306,423 and reducing his direct holdings by 21.27% to 48,478 shares.
- CeriBell’s latest quarterly results missed earnings expectations, reporting a loss of $0.51 per share versus the $0.47 consensus estimate, though revenue of $28.1 million exceeded forecasts.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $22; BTIG and Canaccord maintained buy ratings with targets of $28 and $26, respectively.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Joseph Michael Taylor sold 13,095 shares of CeriBell stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $23.40, for a total transaction of $306,423.00. Following the completion of the transaction, the director directly owned 48,478 shares of the company's stock, valued at approximately $1,134,385.20. This trade represents a 21.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Joseph Michael Taylor also recently made the following trade(s):
- On Thursday, June 11th, Joseph Michael Taylor sold 5,500 shares of CeriBell stock. The shares were sold at an average price of $18.41, for a total transaction of $101,255.00.
CeriBell Trading Up 0.3%
Shares of NASDAQ:CBLL opened at $23.33 on Friday. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $24.33. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.01 and a current ratio of 9.18. The company has a market capitalization of $895.41 million, a P/E ratio of -13.26 and a beta of 0.81. The company has a 50-day simple moving average of $18.93 and a 200 day simple moving average of $19.11.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.04). The business had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Sell-side analysts forecast that CeriBell, Inc. will post -1.96 earnings per share for the current year.
Analysts Set New Price Targets
A number of research firms recently weighed in on CBLL. BTIG Research restated a "buy" rating and issued a $28.00 price target on shares of CeriBell in a research note on Tuesday. Canaccord Genuity Group lifted their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Weiss Ratings upgraded shares of CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $22.00.
Read Our Latest Stock Analysis on CeriBell
Institutional Trading of CeriBell
Several hedge funds have recently added to or reduced their stakes in the company. PDT Partners LLC bought a new stake in CeriBell in the 2nd quarter valued at $1,026,000. Legal & General Group Plc bought a new position in CeriBell during the 2nd quarter worth $53,000. Quantbot Technologies LP bought a new position in CeriBell during the 2nd quarter worth $112,000. Landscape Capital Management L.L.C. acquired a new stake in shares of CeriBell during the second quarter worth $2,078,000. Finally, BlackRock Inc. bought a new stake in shares of CeriBell in the second quarter valued at about $37,657,000.
CeriBell Company Profile
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
